{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:21:13Z","timestamp":1791307273468,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006416","name":"Universidade Estadual De Campinas","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006416","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      To compare the diagnostic performance of [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG and [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA\u20111007 PET\/CT for detecting primary tumors, regional lymph node involvement, and distant metastases in recently diagnosed muscle\u2011invasive bladder cancer (MIBC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective single\u2011center cohort of six patients (ages 57\u201382). Both PET\/CTs were acquired within 30\u00a0days under EANM\/SNMMI-conformant protocols, with blinded consensus readings and post-diuretic pelvic acquisitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA\u20111007 identified 15 lesions versus 14 with [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG. Primary bladder lesions were detected in 5 of 6 patients, compared to 3 of 6 patients. Both tracers detected nodal metastases in three patients and bone metastases in one. An [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG\u2011avid pulmonary lesion near the spleen was not detected with [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA\u20111007 owing to physiological splenic uptake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Both tracers showed comparable sensitivity for metastatic disease. The hepatobiliary clearance of [\n                      <jats:sup>18<\/jats:sup>\n                      F]PSMA\u20111007 improved visualization of intravesical disease, supporting its use in staging and potential theranostic strategies in selected MIBC patients. Such real-world findings inform refinements for future study procedures, logistics, and methodological design, which are essential for minimizing research waste by identifying potential problems early.\n                    <\/jats:p>\n                    <jats:p>Trial Registration: Not applicable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s11307-026-02085-w","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T18:32:39Z","timestamp":1774290759000},"page":"269-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of [18F]FDG and [18F]PSMA-1007 PET\/CT in the Evaluation of Muscle-Invasive Bladder Cancer: A Pilot Feasibility Study"],"prefix":"10.1007","volume":"28","author":[{"given":"Nat\u00e1lia Dalsenter","family":"Avilez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo N.","family":"Tineo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliano Tom\u00e9","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur Degani","family":"Ottaiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena P. A.","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara Juarez","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Barreto Campello","family":"Carvalheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-414X","authenticated-orcid":false,"given":"Leonardo O.","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celso Dario","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"1","key":"2085_CR1","doi-asserted-by":"publisher","DOI":"10.14440\/bladder.2024.0045","volume":"12","author":"HRM Roesch","year":"2025","unstructured":"Roesch HRM, Jalalizadeh M, de Oliveira C, Reis LO (2025) Trends in surgical procedures for bladder cancer within the Brazilian public health system: an 11-year analysis. Bladder 12(1):e21200030","journal-title":"Bladder"},{"issue":"9","key":"2085_CR2","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1007\/s003300050916","volume":"9","author":"JO Barentsz","year":"1999","unstructured":"Barentsz JO, Engelbrecht MR, Witjes JA, de la Rosette JJ, van der Graaf M (1999) MR imaging of the male pelvis. Eur Radiol 9(9):1722\u20131736. https:\/\/doi.org\/10.1007\/s003300050916","journal-title":"Eur Radiol"},{"issue":"2","key":"2085_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17020232","volume":"17","author":"S McDonald","year":"2025","unstructured":"McDonald S, Keane KG, Gauci R, Hayne D (2025) Nuclear medicine and molecular imaging in urothelial cancer: current status and future directions. Cancers (Basel) 17(2):232. https:\/\/doi.org\/10.3390\/cancers17020232","journal-title":"Cancers (Basel)"},{"key":"2085_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1238333","volume":"10","author":"J Dang","year":"2023","unstructured":"Dang J, Yao Y, Li Y, Tan X, Ye Z, Zhao Y, Qing S, Kou Y, Jiang X, Lu H, Chen S, Zhao M, Cheng Z (2023) An exploratory study of unexplained concentration of 18F-PSMA-1007 in the bladder for prostate cancer PET\/CT imaging. Front Med 10:1238333. https:\/\/doi.org\/10.3389\/fmed.2023.1238333","journal-title":"Front Med"},{"issue":"2","key":"2085_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ, European Association of Nuclear Medicine (EANM) (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328\u2013354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2085_CR6","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Sch\u00f6der H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K (2017) 68Ga-PSMA PET\/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44(6):1014\u20131024. https:\/\/doi.org\/10.1007\/s00259-017-3670-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"2085_CR7","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s00345-018-2384-6","volume":"36","author":"HA Garc\u00eda-Perdomo","year":"2018","unstructured":"Garc\u00eda-Perdomo HA, Montes-Cardona CE, Guacheta M, Castillo DF, Reis LO (2018) Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis. World J Urol 36(12):1997\u20132008. https:\/\/doi.org\/10.1007\/s00345-018-2384-6","journal-title":"World J Urol"},{"issue":"1","key":"2085_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eururo.2006.05.021","volume":"51","author":"SF Shariat","year":"2007","unstructured":"Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y (2007) Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51(1):137\u2013151. https:\/\/doi.org\/10.1016\/j.eururo.2006.05.021","journal-title":"Eur Urol"},{"issue":"4","key":"2085_CR9","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00345-018-2439-8","volume":"37","author":"J Crozier","year":"2019","unstructured":"Crozier J, Papa N, Perera M, Ngo B, Bolton D, Sengupta S, Lawrentschuk N (2019) Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis. World J Urol 37(4):667\u2013690. https:\/\/doi.org\/10.1007\/s00345-018-2439-8","journal-title":"World J Urol"},{"issue":"1","key":"2085_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes J, Max Bruins H, Carri\u00f3n A, Cathomas R, Comp\u00e9rat E, Efstathiou JA, Fietkau R, Gakis G, Lorch A, Martini A, Mertens LS, Meijer RP, Milowsky MI, Neuzillet Y, Panebianco V, Redlef J, Rink M, Rouanne M, Thalmann GN, S\u00e6bj\u00f8rnsen S, van der Heijden AG (2024) European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 85(1):17\u201331. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.016","journal-title":"Eur Urol"},{"issue":"4","key":"2085_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/bju.16091","volume":"132","author":"A Richters","year":"2023","unstructured":"Richters A, van Ginkel N, Meijer RP, Wondergem M, Schoots I, Vis AN, Kiemeney LALM, van Rhijn BWG, Witjes JA, Aben KKH, Mertens LS (2023) Staging fluorodeoxyglucose positron emission tomography\/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study. BJU Int 132(4):420\u2013427. https:\/\/doi.org\/10.1111\/bju.16091","journal-title":"BJU Int"},{"issue":"1","key":"2085_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1590\/s1677-5538.ibju.2021.0329","volume":"48","author":"L Eismann","year":"2022","unstructured":"Eismann L, Rodler S, Tamalunas A, Schulz G, Jokisch F, Volz Y et al (2022) Computed-tomography based scoring system predicts outcome for clinical lymph node-positive patients undergoing radical cystectomy. Int Braz J Urol 48(1):89\u201398","journal-title":"Int Braz J Urol"},{"issue":"7","key":"2085_CR13","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s00345-022-04010-6","volume":"40","author":"S Rodler","year":"2022","unstructured":"Rodler S, Solyanik O, Ingenerf M, Fabritius M, Schulz GB, Jokisch F et al (2022) Accuracy and prognostic value of radiological lymph node features in variant histologies of bladder cancer. World J Urol 40(7):1707\u20131714","journal-title":"World J Urol"},{"issue":"6","key":"2085_CR14","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.2214\/AJR.08.1318","volume":"192","author":"R Vikram","year":"2009","unstructured":"Vikram R, Sandler CM, Ng CS (2009) Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract. AJR Am J Roentgenol 192(6):1481\u20131487","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"2085_CR15","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4103\/iju.iju_462_23","volume":"40","author":"BV Reddy","year":"2024","unstructured":"Reddy BV, Gali KV, Chawla A, Singh A, Bhaskara SP, Hegde P (2024) Performance and clinical implications of VI-RADS in detecting muscle invasion in bladder tumors: a prospective observational study. Indian J Urol 40(4):243\u2013249","journal-title":"Indian J Urol"},{"issue":"4","key":"2085_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14040442","volume":"14","author":"K He","year":"2024","unstructured":"He K, Meng X, Wang Y, Feng C, Liu Z, Li Z et al (2024) Progress of multiparameter magnetic resonance imaging in bladder cancer: a comprehensive literature review. Diagnostics 14(4):442","journal-title":"Diagnostics"},{"key":"2085_CR17","first-page":"13","volume":"25","author":"D S\u00e9guier","year":"2021","unstructured":"S\u00e9guier D, Puech P, Kool R, Dernis L, Gabert H, Kassouf W et al (2021) Multiparametric magnetic resonance imaging for bladder cancer: a comprehensive systematic review of the Vesical Imaging-Reporting and Data System (VI-RADS) performance and potential clinical applications. Ther Adv Urol 25:13","journal-title":"Ther Adv Urol"},{"issue":"11","key":"2085_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112951","volume":"15","author":"M Bacchiani","year":"2023","unstructured":"Bacchiani M, Salamone V, Massaro E, Sandulli A, Mariottini R, Cadenar A et al (2023) Assessing the performance of 18F-FDG PET\/CT in bladder cancer: a narrative review of current evidence. Cancers (Basel) 15(11):2951","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2085_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03020-1","volume":"16","author":"AS Abdlkadir","year":"2025","unstructured":"Abdlkadir AS, Al-Adhami D, Allouzi S, Badarneh M, Shahait M, Abdulrahman M et al (2025) Diagnostic efficacy of [18F]FDG PET\/CT and [18F]FDG PET\/MRI in preoperative staging of locoregional urinary bladder cancer: a systematic review and meta-analysis. Discover Oncology 16(1):1241","journal-title":"Discover Oncology"},{"issue":"5","key":"2085_CR20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2024.07.023","volume":"86","author":"JJ de Jong","year":"2024","unstructured":"de Jong JJ, Lotan Y, Boormans JL (2024) Re: EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 86(5):480\u2013481","journal-title":"Eur Urol"},{"issue":"11","key":"2085_CR21","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1038\/modpathol.2011.112","volume":"24","author":"MK Samplaski","year":"2011","unstructured":"Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE (2011) Folate hydrolase (prostate-specific membrane antigen) 1 expression in bladder cancer subtypes and associated tumour neovasculature. Mod Pathol 24(11):1521\u20131529. https:\/\/doi.org\/10.1038\/modpathol.2011.112","journal-title":"Mod Pathol"},{"issue":"13","key":"2085_CR22","first-page":"3192","volume":"59","author":"SS Chang","year":"1999","unstructured":"Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumour-associated neovasculature. Cancer Res 59(13):3192\u20133198","journal-title":"Cancer Res"},{"issue":"10","key":"2085_CR23","first-page":"4049","volume":"6","author":"JL Gala","year":"2000","unstructured":"Gala JL, Loric S, Guiot Y, Denmeade SR, Gady A, Brasseur F, Heusterspreute M, Eschw\u00e8ge P, De Nayer P, Van Cangh P, Tombal B (2000) Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res 6(10):4049\u20134054","journal-title":"Clin Cancer Res"},{"key":"2085_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.771036","volume":"11","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang K, Yang F, Jiao D, Li M, Zhao X, Xu C, Liu S, Li H, Shi S, Yang B, Yang L, Han D, Wen W, Qin W (2021) Prognostic value of vascular-expressed PSMA and CD248 in urothelial carcinoma of the bladder. Front Oncol 11:771036. https:\/\/doi.org\/10.3389\/fonc.2021.771036","journal-title":"Front Oncol"},{"issue":"2","key":"2085_CR25","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00432-019-03113-9","volume":"146","author":"H Schreiber","year":"2020","unstructured":"Schreiber H, H\u00e4nze J, Nimphius W, Verburg FA, Luster M, Hofmann R, Hegele A (2020) Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumour grading and staging. J Cancer Res Clin Oncol 146(2):305\u2013313. https:\/\/doi.org\/10.1007\/s00432-019-03113-9","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2085_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12149-017-1216-x","volume":"32","author":"SP Campbell","year":"2018","unstructured":"Campbell SP, Baras AS, Ball MW, Kates M, Hahn NM, Bivalacqua TJ, Johnson MH, Pomper MG, Allaf ME, Rowe SP, Gorin MA (2018) Low levels of PSMA expression limit the utility of 18F-DCFPyL PET\/CT for imaging urothelial carcinoma. Ann Nucl Med 32(1):69\u201374. https:\/\/doi.org\/10.1007\/s12149-017-1216-x","journal-title":"Ann Nucl Med"},{"issue":"11","key":"2085_CR27","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1007\/s11255-023-03710-1","volume":"55","author":"BH Lin","year":"2023","unstructured":"Lin BH, Chen SH, Chen SM, Qiu QR, Gao RC, Wei Y, Zheng QS, Miao WB, Xu N (2023) Head-to-head comparisons of 68Ga-PSMA-11 and 18F-FDG PET\/CT in evaluating patients with upper tract urothelial carcinoma: a prospective pilot study. Int Urol Nephrol 55(11):2753\u20132764. https:\/\/doi.org\/10.1007\/s11255-023-03710-1","journal-title":"Int Urol Nephrol"},{"issue":"5 Suppl","key":"2085_CR28","first-page":"S63","volume":"33","author":"SR Kudachi","year":"2018","unstructured":"Kudachi SR, Karthik S, Singh A, Kumar R, Mittal BR (2018) Prostate-specific membrane antigen expression in metastatic transitional cell carcinoma detected on 68Ga prostate-specific membrane antigen positron emission tomography\/computed tomography scan: a potential molecular target for imaging and therapy in transitional cell carcinoma. Indian J Nucl Med 33(5 Suppl):S63","journal-title":"Indian J Nucl Med"},{"issue":"1","key":"2085_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/j.semnuclmed.2023.07.002","volume":"54","author":"H Duan","year":"2024","unstructured":"Duan H, Iagaru A (2024) PSMA PET for detection of recurrence. Semin Nucl Med 54(1):77\u201386. https:\/\/doi.org\/10.1053\/j.semnuclmed.2023.07.002","journal-title":"Semin Nucl Med"},{"key":"2085_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.585213","volume":"10","author":"X Zhou","year":"2021","unstructured":"Zhou X, Li Y, Jiang X, Wang X, Chen S, Shen T, You J, Lu H, Liao H, Li Z, Cheng Z (2021) Intra-individual comparison of 18F-PSMA-1007 and 18F-FDG PET\/CT in the evaluation of patients with prostate cancer. Front Oncol 10:585213. https:\/\/doi.org\/10.3389\/fonc.2020.585213","journal-title":"Front Oncol"},{"issue":"19_Suppl","key":"2085_CR31","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2014-CT413","volume":"74","author":"O Pail","year":"2014","unstructured":"Pail O, Kaur G, Dyke J, Jhanwar Y, Christos P, Ocean A, Shah M, Shore T, Schneider B, Scheff R, Beltran H, Ballon D, Robinson B, Nanus DM, Bander NH, Tagawa ST (2014) Lutetium-177-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic non-prostate solid tumours. Cancer Res 74(19_Suppl):CT413. https:\/\/doi.org\/10.1158\/1538-7445.AM2014-CT413","journal-title":"Cancer Res"},{"issue":"12","key":"2085_CR32","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1007\/s00259-023-06406-x","volume":"50","author":"P Veit-Haibach","year":"2023","unstructured":"Veit-Haibach P, Ahlstr\u00f6m H, Boellaard R, Delgado Bolton RC, Hesse S, Hope T, Huellner MW, Iagaru A, Johnson GB, Kjaer A, Law I, Metser U, Quick HH, Sattler B, Umutlu L, Zaharchuk G, Herrmann K (2023) International EANM-SNMMI-ISMRM consensus recommendation for PET\/MRI in oncology. Eur J Nucl Med Mol Imaging 50(12):3513\u20133537. https:\/\/doi.org\/10.1007\/s00259-023-06406-x","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-026-02085-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-026-02085-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:37:32Z","timestamp":1778506652000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-026-02085-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2085"],"URL":"https:\/\/doi.org\/10.1007\/s11307-026-02085-w","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its subsequent amendments, following approval by the University of Campinas (UNICAMP) Ethics Committee (CAAE: 60,267,622.0.0000.5404, approved on October 21, 2022). All the participants signed informed consent forms before participating.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"No potential conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}